Table 2.
Treatment | Number of subjects completing the study | Age | Compliance | Tolerability | Dropouts |
---|---|---|---|---|---|
150 mg + best management | 37 (14 females) | 51.33; 5.31 | 94% | Very good | 0 |
300 mg + best management | 35 (18 females) | 49.9; 5.2 | 95% | Very good | 0 |
Best management | 47 (19 females) | 49.4; 3 | 95% | Very good | 3 |